Gonilert (Sodium Hyaluronate)

Gonilert is indicated for the symptomatic treatment of osteoarthritis and other degenerative joint conditions where joint lubrication is compromised.

• Intra‑articular injection for knee osteoarthritis to improve joint function.
• Management of hip or shoulder osteoarthritis when conventional therapy is insufficient.
• Adjunct therapy for patients with limited response to oral analgesics or NSAIDs.
• Use in patients awaiting joint replacement surgery to potentially delay the procedure.
• Treatment of post‑traumatic joint stiffness to restore range of motion.

The safety profile of Gonilert reflects the typical reactions observed with intra‑articular hyaluronic acid preparations.

Common

• Transient joint pain or swelling at the injection site.
• Mild warmth or flushing in the treated joint.
• Temporary stiffness lasting a few days.
• Minor bruising or bleeding at the puncture site.

Serious

• Acute joint infection (septic arthritis).
• Allergic reaction such as rash, itching, or anaphylaxis.

Clinicians should evaluate patient history and joint condition before selecting Gonilert for intra‑articular therapy.

• Avoid use in patients with active joint infection or systemic infection.
• Contraindicated in individuals with known hypersensitivity to hyaluronic acid or any formulation component.
• Use caution in patients with bleeding disorders or those receiving anticoagulant therapy.
• Assess renal function in patients with severe kidney disease, as clearance may be affected.
• Do not inject into joints with severe cartilage loss where structural benefit is unlikely.
• Monitor for signs of infection or inflammation after each injection.
• Discuss potential risks with pregnant or breastfeeding women, although safety data are limited.

Gonilert may interact with other medications or substances that affect joint health or bleeding risk.

Avoid

• Concurrent intra‑articular corticosteroid injections within the same joint.
• Simultaneous use of other viscosupplement products in the same joint.

Use with caution

• Systemic anticoagulants (e.g., warfarin, direct oral anticoagulants) due to bleeding risk at injection site.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may increase local irritation.
• Disease‑modifying antirheumatic drugs (DMARDs) in patients with inflammatory arthritis.
• High‑dose vitamin C or supplements that affect collagen synthesis.